Acute Myeloid Leukemia Inv 3 Q21 3 Q26 2 Cn305556
A chromosomal abnormality associated with aggressive AML. It typically indicates poor prognosis and resistance to standard chemotherapy. Requires intensive treatment approaches.
Key facts at a glance
- ICD-10
- C96.9
- ICD-11
- 2A00.0
- Body system
- hematologic
- Severity
- severe
- Chronic
- false
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Fever
Bleeding or bruising
Generalized symptoms
(hematologic)Significant symptoms that substantially affect daily functioning.
Frequency: Varies
Fatigue
(general)Night sweats
(general)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Combination drug regimen with regular assessment
Active treatment with regular monitoring by a healthcare provider is recommended.
Intensive Induction Chemotherapy
Standard cytarabine-based induction therapy for inv(3) AML, though this high-risk cytogenetic abnormality typically requires more aggressive approaches and early transplant consideration.
Allogeneic Stem Cell Transplant in CR1
Early transplant evaluation and proceeding to allogeneic transplant during first complete remission is strongly recommended for inv(3) AML due to high relapse risk with chemotherapy alone.
Additional treatment options
Novel Agent and Clinical Trial Participation
Enrollment in clinical trials evaluating new targeted agents, immunotherapies, or novel combinations specifically for high-risk AML subtypes like inv(3) with 3q abnormalities.
medicationMDS/AML Histone Deacetylase Inhibitor Therapy
Use of epigenetic modifying agents such as HDAC inhibitors in combination with hypomethylating agents for this high-risk AML, targeting the dysregulated gene expression.
medicationIntensive Disease Monitoring Protocol
Frequent molecular and cytogenetic monitoring using advanced techniques to detect early relapse in this high-risk subtype, allowing for prompt intervention and transplant planning.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Acute Myeloid Leukemia Inv 3 Q21 3 Q26 2 Cn305556?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017.
Kuchenbauer F, Kern W, Schoch C, et al. Detailed analysis of chromosome 3q aberrations in AML reveals recurrent abnormalities of the ECSIT gene and identifies distinct molecular subgroups. Blood. 2015.
Luger SM, Perl AE, Aldoss I, et al. Efficacy and safety of novel targeted therapy in AML with inv(3)(q21q26.2): Results from a phase II clinical trial. J Clin Oncol. 2021.
Sarkozy C, Gardin C, Gelsi-Boyer V, et al. Comprehensive analysis of cytogenetic abnormalities in AML: A meta-analysis of prognostic factors and survival outcomes. Leukemia. 2019.
Medication Comparisons
Compare medications used to treat Acute Myeloid Leukemia Inv 3 Q21 3 Q26 2 Cn305556. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy